At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AIM AIM ImmunoTech Inc.
Trading 07-27 13:03:14 EDT
0.2425
-0.0065
-2.61%
High0.2544Low0.2402Vol182.91K
Open0.2500D1 Closing0.2490Amplitude5.70%
Mkt Cap6.72MTradable Cap6.06MTotal Shares27.72M
T/O45.04KT/O Rate0.73%Tradable Shares24.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Restore plc to Cancel Shares After AIM Buyback Programme
TIPRANKS  ·  07-27 16:32
Restore plc to Cancel Shares After AIM Buyback Programme
Gelion Leaves Share Option Pool Unchanged in Latest AIM Block Admission Update
TIPRANKS  ·  07-27 14:42
Gelion Leaves Share Option Pool Unchanged in Latest AIM Block Admission Update
Big Four’s AIM exodus accelerates as mid-tier firms seize mandates
cityam  ·  07-27 13:00
Big Four’s AIM exodus accelerates as mid-tier firms seize mandates
Kibo Energy to Delist from AIM as Reverse Takeover Falls Through
TIPRANKS  ·  07-24
Kibo Energy to Delist from AIM as Reverse Takeover Falls Through
Octopus AIM VCT secures shareholder backing at annual meeting
TIPRANKS  ·  07-23
Octopus AIM VCT secures shareholder backing at annual meeting
Octopus AIM VCT Cuts Share Capital Through Targeted Buyback
TIPRANKS  ·  07-23
Octopus AIM VCT Cuts Share Capital Through Targeted Buyback
Boku Tightens Capital Structure with Fresh Share Buyback on AIM
TIPRANKS  ·  07-23
Boku Tightens Capital Structure with Fresh Share Buyback on AIM
Mercia continues share buyback, trims share count on AIM
TIPRANKS  ·  07-23
Mercia continues share buyback, trims share count on AIM
Octopus AIM VCT 2 Delivers Modest Half-Year Gains Amid Market Volatility and Regulatory Change
TIPRANKS  ·  07-22
Octopus AIM VCT 2 Delivers Modest Half-Year Gains Amid Market Volatility and Regulatory Change
Layoffs and an executive exit: What’s going on at London’s first listed law firm?
cityam  ·  07-22
Layoffs and an executive exit: What’s going on at London’s first listed law firm?
Puma AIM VCT Clarifies Subscription Offer and Sets Closing Date
TIPRANKS  ·  07-21
Puma AIM VCT Clarifies Subscription Offer and Sets Closing Date
Insig AI Pushes Back AIM Admission Date for New Share Issue
TIPRANKS  ·  07-21
Insig AI Pushes Back AIM Admission Date for New Share Issue
Clean Power Hydrogen Wins Shareholder Backing and Raises £7.3m on AIM
TIPRANKS  ·  07-20
Clean Power Hydrogen Wins Shareholder Backing and Raises £7.3m on AIM
Volex to Shift Listing from AIM to London Stock Exchange Main Market
TIPRANKS  ·  07-20
Volex to Shift Listing from AIM to London Stock Exchange Main Market
Restore plc Cancels Shares After July Buyback on AIM
TIPRANKS  ·  07-20
Restore plc Cancels Shares After July Buyback on AIM
Hargreave Hale AIM VCT Sets DRIS Share Price and Dividend Timetable
TIPRANKS  ·  07-20
Hargreave Hale AIM VCT Sets DRIS Share Price and Dividend Timetable
AMS publishes scheme document for H.B. Fuller cash takeover and AIM delisting
TIPRANKS  ·  07-20
AMS publishes scheme document for H.B. Fuller cash takeover and AIM delisting
Unicorn AIM VCT Cancels Shares After Targeted Buyback
TIPRANKS  ·  07-20
Unicorn AIM VCT Cancels Shares After Targeted Buyback
M.P. Evans tightens share count with latest buyback on AIM
TIPRANKS  ·  07-17
M.P. Evans tightens share count with latest buyback on AIM
AIM Immunotech Shareholders Approve Stock Issuance Proposals at Special Meeting
Reuters  ·  07-17
AIM Immunotech Shareholders Approve Stock Issuance Proposals at Special Meeting

Introduction

Company Name.
AIM ImmunoTech Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Issue price:
--